Is XFOR or XOMAP more undervalued in 2026?

CirclFi compares X4 Pharmaceuticals, Inc. (XFOR) and XOMA Royalty Corporation - 8.62 (XOMAP) using 13 institutional-grade valuation models. XFOR has a Quality of Company score of 5.1/10 while XOMAP scores 8.2/10.

Which is a better buy — XFOR or XOMAP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do XFOR and XOMAP valuations compare?

XFOR at $4.14 and XOMAP at $25.45 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

XFOR vs XOMAP Valuation Comparison 2026 — Intrinsic Value Analysis

XFOR

Biotechnology

X4 Pharmaceuticals, Inc.

Quality

5.1

out of 10

Value Trap

WARN

Price

$4.14

Last close

Models

11/13

Active

XOMAP

Biotechnology

XOMA Royalty Corporation - 8.62

Quality

8.2

out of 10

Value Trap

SAFE

Price

$25.45

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	XFOR Fair Value	XFOR Upside	XOMAP Fair Value	XOMAP Upside
Bayesian DCF	Intrinsic	$2.03	-51.0%	$18.97	-25.2%
Earnings Power Value	Intrinsic	$3.32	-20.8%	$4.93	-80.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for XFOR vs XOMAP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

XFOR vs XOMAP — Which Stock Is More Undervalued?

XOMAP scores higher with a 8.2/10 quality rating vs XFOR's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing X4 Pharmaceuticals, Inc. (XFOR) and XOMA Royalty Corporation - 8.62 (XOMAP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

XFOR currently trades at $4.14 with a QOC of 5.1/10, while XOMAP trades at $25.45 with a QOC of 8.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).